Journal of Atrial Fibrillation & Electrophysiology Publishes Special Issue Dedicated to Robotics in EP
06 Juin 2022 - 03:07PM
GlobeNewswire Inc.
Stereotaxis (NYSE: STXS), the global leader in innovative robotic
technologies for the treatment of cardiac arrhythmias, announces
the publication of a special issue of the Journal of Atrial
Fibrillation & Electrophysiology (JAFIB-EP) focused on the use
of Robotic Magnetic Navigation (RMN) for the treatment of cardiac
arrhythmias. The Robotics Special Issue was published in
collaboration with the Society for Cardiac Robotic Navigation and
includes sixteen peer-reviewed publications that document the
clinical value of Robotic Magnetic Navigation, new technologies,
and refined workflows across a broad spectrum of cardiac
arrhythmias. The journal will also incorporate robotics as a
recurring section in future editions.
Physicians from 20 hospitals and universities
throughout North America, Europe and Asia contributed to the
sixteen publications in the Robotics Special Issue. The complete
issue can be accessed at www.JAFIB-EP.com. The publications cover a
wide range of topics including:
- Historical review and evolution of
Robotic Magnetic Navigation
- Reviews of clinical outcomes from
large subsets of patients with atrial fibrillation, ventricular
tachycardias and supraventricular tachycardias
- Robotics enabling fluoro-less
cardiac ablation procedures without the use of x-ray radiation
- The use of Stereotaxis robotic
technology in conjunction with novel preoperative imaging and a
broad array of electrophysiology mapping technologies
- Demonstration of TeleRobotic
technology for remote catheter navigation
“Robotics represents increasingly important
technology for the field of electrophysiology,” said Dr. Andrea
Natale, Editor-in-Chief of the Journal of Atrial Fibrillation &
Electrophysiology. “We are delighted to collaborate with the
Society for Cardiac Robotic Navigation on this special issue and to
contribute to the advancement of clinical science and
awareness.”
“We seem to be at an important inflection point
in the evolution of robotic magnetic navigation in
electrophysiology,” said Dr. J. Peter Weiss, President of the
Society for Cardiac Robotic Navigation. “As the field continues to
optimize safety, efficacy and efficiency in the care of arrhythmia
patients, the increasing adoption of robotics and automation is
poised to play an essential role. We hope this special edition
provides education, motivation and inspiration to all who are
interested in moving the field forward.”
The Journal of Atrial Fibrillation &
Electrophysiology was founded in 2008. Its mission is to provide a
forum for communicating original and innovative research findings
that have relevance in better understanding the pathophysiology of
cardiac arrhythmias and improving the treatment and survival of
patients. Tens of millions of individuals worldwide suffer from
arrhythmias – abnormal heart rhythms that result when the heart
beats too quickly, too slowly or with an irregular pattern. When
left untreated, arrhythmias may significantly increase the risk of
stroke, heart failure and sudden cardiac arrest. Robotic Magnetic
Navigation introduces the benefits of robotic precision and safety
to cardiac ablation. Robotic cardiac ablation is performed using a
soft magnetic catheter navigated inside the heart by a physician
seated at a computer cockpit. The physician navigates the catheter
using precise, robotically actuated magnets positioned on either
side of the patient.
“A growing body of scientific literature
continues to support the differentiated clinical value of robotics
for the treatment of a broad range of arrhythmias,” said David
Fischel, Chairman and CEO of Stereotaxis. “We are delighted to be
advancing the frontiers of patient care and technology in
electrophysiology.”
About StereotaxisStereotaxis is
the global leader in innovative robotic technologies designed to
enhance the treatment of arrhythmias and perform endovascular
procedures. Its mission is the discovery, development and delivery
of robotic systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
expand access to minimally invasive therapy, and enhance the
productivity, connectivity, and intelligence in the operating room.
Stereotaxis technology has been used to treat over 100,000 patients
across the United States, Europe, Asia, and elsewhere. For more
information, please visit www.stereotaxis.com.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Investor Contacts: |
Media Contact: |
David L. Fischel |
Bethanne Schluter |
Chairman and Chief Executive Officer |
Director, Marketing & Communications |
|
314-678-6213 |
Kimberly Peery |
Bethanne.Schluter@Stereotaxis.com |
Chief Financial Officer |
|
|
|
314-678-6100 |
|
Investors@Stereotaxis.com |
|
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Mar 2023 à Mar 2023
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Mar 2022 à Mar 2023